Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023
Objectives: We evaluated the vaccine effectiveness of monovalent XBB.1.5 vaccine against symptomatic COVID-19 infection, hospitalization, and the need for oxygen therapy in South Korea. Design: This study employed a test-negative case-control design. COVID-19 test results in symptomatic subjects fro...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-11-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971224003205 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850203007854051328 |
|---|---|
| author | Jung Ah Lee Heeseon Jang Sang Min Ahn Jae Eun Seong Young Keun Kim Yujin Sohn Sook In Jung Hye Won Jeong Shin-Woo Kim Jin-Soo Lee Ji-Hyeon Baek Se Ju Lee Geun-Yong Kwon Jeeyeon Shin Hangjin Jeong Changsoo Kim Jun Yong Choi |
| author_facet | Jung Ah Lee Heeseon Jang Sang Min Ahn Jae Eun Seong Young Keun Kim Yujin Sohn Sook In Jung Hye Won Jeong Shin-Woo Kim Jin-Soo Lee Ji-Hyeon Baek Se Ju Lee Geun-Yong Kwon Jeeyeon Shin Hangjin Jeong Changsoo Kim Jun Yong Choi |
| author_sort | Jung Ah Lee |
| collection | DOAJ |
| description | Objectives: We evaluated the vaccine effectiveness of monovalent XBB.1.5 vaccine against symptomatic COVID-19 infection, hospitalization, and the need for oxygen therapy in South Korea. Design: This study employed a test-negative case-control design. COVID-19 test results in symptomatic subjects from six university hospitals across South Korea were collected (October 26–December 31, 2023). The adjusted absolute and relative vaccine effectiveness were assessed. Results: In total, 5516 subjects were enrolled: 4,824 were unvaccinated with XBB.1.5, and 692 were vaccinated with XBB.1.5 COVID-19 mRNA vaccines. The absolute vaccine effectiveness when comparing the odds between XBB.1.5 vaccination and no vaccination against symptomatic COVID-19 infection, hospitalization, and oxygen therapy was 65.2% (95% CI, 36.1-81.0), 77.3% (95% CI, 51.1-89.5), and 85.3% (95% CI, 57.8-94.9), respectively. The relative vaccine effectiveness when comparing the odds between XBB.1.5 vaccination and no XBB.1.5 vaccination against symptomatic COVID-19 infection, hospitalization, and oxygen therapy was 57.7% (95% CI, 34.7-72.6), 64.3% (95% CI, 35.9-80.2), and 65.5% (95% CI, 27.0-83.7), respectively. Conclusion: The short-term effectiveness of the XBB.1.5 vaccine against symptomatic COVID-19 infection, hospitalization, and receipt of oxygen therapy in South Korea was significant. Long-term vaccine effectiveness warrants evaluation, and these assessments should be conducted regularly. |
| format | Article |
| id | doaj-art-d1000e63cd0a44a3995d31dac7e3536f |
| institution | OA Journals |
| issn | 1201-9712 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj-art-d1000e63cd0a44a3995d31dac7e3536f2025-08-20T02:11:37ZengElsevierInternational Journal of Infectious Diseases1201-97122024-11-0114810724910.1016/j.ijid.2024.107249Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023Jung Ah Lee0Heeseon Jang1Sang Min Ahn2Jae Eun Seong3Young Keun Kim4Yujin Sohn5Sook In Jung6Hye Won Jeong7Shin-Woo Kim8Jin-Soo Lee9Ji-Hyeon Baek10Se Ju Lee11Geun-Yong Kwon12Jeeyeon Shin13Hangjin Jeong14Changsoo Kim15Jun Yong Choi16Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of KoreaDepartment of Preventive Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of KoreaDivision of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of KoreaDivision of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of KoreaDepartment of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of KoreaDepartment of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of KoreaDepartment of Infectious Diseases, Chonnam National University Medical School, Dong-gu, Gwangju, Republic of KoreaDepartment of Internal Medicine, Chungbuk National University College of Medicine, Seowon-gu, Cheongju, Republic of KoreaDepartment of Internal Medicine, Kyungpook National University School of Medicine, Jung-gu, Daegu, Republic of KoreaDivision of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Michuhol-gu, Incheon, Republic of KoreaDivision of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Michuhol-gu, Incheon, Republic of KoreaDivision of Infectious Diseases, Department of Internal Medicine, Inha University College of Medicine, Michuhol-gu, Incheon, Republic of KoreaDivision of Immunization, Korea Disease Control and Prevention Agency, Heungdeok-gu, Cheongju, Republic of KoreaDivision of Immunization, Korea Disease Control and Prevention Agency, Heungdeok-gu, Cheongju, Republic of KoreaDivision of Immunization, Korea Disease Control and Prevention Agency, Heungdeok-gu, Cheongju, Republic of KoreaDepartment of Preventive Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of KoreaDivision of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of Korea; Corresponding author: Jun Yong Choi, Division of Infectious disease and AIDS Research Institute, Department of Internal Medicine, Yonsei University College of Medicine, Yonsei University Health System, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.Objectives: We evaluated the vaccine effectiveness of monovalent XBB.1.5 vaccine against symptomatic COVID-19 infection, hospitalization, and the need for oxygen therapy in South Korea. Design: This study employed a test-negative case-control design. COVID-19 test results in symptomatic subjects from six university hospitals across South Korea were collected (October 26–December 31, 2023). The adjusted absolute and relative vaccine effectiveness were assessed. Results: In total, 5516 subjects were enrolled: 4,824 were unvaccinated with XBB.1.5, and 692 were vaccinated with XBB.1.5 COVID-19 mRNA vaccines. The absolute vaccine effectiveness when comparing the odds between XBB.1.5 vaccination and no vaccination against symptomatic COVID-19 infection, hospitalization, and oxygen therapy was 65.2% (95% CI, 36.1-81.0), 77.3% (95% CI, 51.1-89.5), and 85.3% (95% CI, 57.8-94.9), respectively. The relative vaccine effectiveness when comparing the odds between XBB.1.5 vaccination and no XBB.1.5 vaccination against symptomatic COVID-19 infection, hospitalization, and oxygen therapy was 57.7% (95% CI, 34.7-72.6), 64.3% (95% CI, 35.9-80.2), and 65.5% (95% CI, 27.0-83.7), respectively. Conclusion: The short-term effectiveness of the XBB.1.5 vaccine against symptomatic COVID-19 infection, hospitalization, and receipt of oxygen therapy in South Korea was significant. Long-term vaccine effectiveness warrants evaluation, and these assessments should be conducted regularly.http://www.sciencedirect.com/science/article/pii/S1201971224003205COVID-19VaccineVaccine effectivenessXBB.1.5 |
| spellingShingle | Jung Ah Lee Heeseon Jang Sang Min Ahn Jae Eun Seong Young Keun Kim Yujin Sohn Sook In Jung Hye Won Jeong Shin-Woo Kim Jin-Soo Lee Ji-Hyeon Baek Se Ju Lee Geun-Yong Kwon Jeeyeon Shin Hangjin Jeong Changsoo Kim Jun Yong Choi Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023 International Journal of Infectious Diseases COVID-19 Vaccine Vaccine effectiveness XBB.1.5 |
| title | Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023 |
| title_full | Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023 |
| title_fullStr | Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023 |
| title_full_unstemmed | Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023 |
| title_short | Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023 |
| title_sort | estimates of vaccine effectiveness of the updated monovalent xbb 1 5 covid 19 vaccine against symptomatic sars cov 2 infection hospitalization and receipt of oxygen therapy in south korea october 26 to december 31 2023 |
| topic | COVID-19 Vaccine Vaccine effectiveness XBB.1.5 |
| url | http://www.sciencedirect.com/science/article/pii/S1201971224003205 |
| work_keys_str_mv | AT jungahlee estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT heeseonjang estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT sangminahn estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT jaeeunseong estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT youngkeunkim estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT yujinsohn estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT sookinjung estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT hyewonjeong estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT shinwookim estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT jinsoolee estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT jihyeonbaek estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT sejulee estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT geunyongkwon estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT jeeyeonshin estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT hangjinjeong estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT changsookim estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 AT junyongchoi estimatesofvaccineeffectivenessoftheupdatedmonovalentxbb15covid19vaccineagainstsymptomaticsarscov2infectionhospitalizationandreceiptofoxygentherapyinsouthkoreaoctober26todecember312023 |